Literature DB >> 24002801

Novel hybrid GPU-CPU implementation of parallelized Monte Carlo parametric expectation maximization estimation method for population pharmacokinetic data analysis.

C M Ng1.   

Abstract

The development of a population PK/PD model, an essential component for model-based drug development, is both time- and labor-intensive. A graphical-processing unit (GPU) computing technology has been proposed and used to accelerate many scientific computations. The objective of this study was to develop a hybrid GPU-CPU implementation of parallelized Monte Carlo parametric expectation maximization (MCPEM) estimation algorithm for population PK data analysis. A hybrid GPU-CPU implementation of the MCPEM algorithm (MCPEMGPU) and identical algorithm that is designed for the single CPU (MCPEMCPU) were developed using MATLAB in a single computer equipped with dual Xeon 6-Core E5690 CPU and a NVIDIA Tesla C2070 GPU parallel computing card that contained 448 stream processors. Two different PK models with rich/sparse sampling design schemes were used to simulate population data in assessing the performance of MCPEMCPU and MCPEMGPU. Results were analyzed by comparing the parameter estimation and model computation times. Speedup factor was used to assess the relative benefit of parallelized MCPEMGPU over MCPEMCPU in shortening model computation time. The MCPEMGPU consistently achieved shorter computation time than the MCPEMCPU and can offer more than 48-fold speedup using a single GPU card. The novel hybrid GPU-CPU implementation of parallelized MCPEM algorithm developed in this study holds a great promise in serving as the core for the next-generation of modeling software for population PK/PD analysis.

Entities:  

Mesh:

Year:  2013        PMID: 24002801      PMCID: PMC3787213          DOI: 10.1208/s12248-013-9524-0

Source DB:  PubMed          Journal:  AAPS J        ISSN: 1550-7416            Impact factor:   4.009


  9 in total

1.  Comparison of Nonmem 7.2 estimation methods and parallel processing efficiency on a target-mediated drug disposition model.

Authors:  Leonid Gibiansky; Ekaterina Gibiansky; Robert Bauer
Journal:  J Pharmacokinet Pharmacodyn       Date:  2011-11-19       Impact factor: 2.745

2.  Performance comparison of various maximum likelihood nonlinear mixed-effects estimation methods for dose-response models.

Authors:  Elodie L Plan; Alan Maloney; France Mentré; Mats O Karlsson; Julie Bertrand
Journal:  AAPS J       Date:  2012-04-14       Impact factor: 4.009

Review 3.  Pharmacokinetics/Pharmacodynamics and the stages of drug development: role of modeling and simulation.

Authors:  Jenny Y Chien; Stuart Friedrich; Michael A Heathman; Dinesh P de Alwis; Vikram Sinha
Journal:  AAPS J       Date:  2005-10-07       Impact factor: 4.009

Review 4.  A survey of population analysis methods and software for complex pharmacokinetic and pharmacodynamic models with examples.

Authors:  Robert J Bauer; Serge Guzy; Chee Ng
Journal:  AAPS J       Date:  2007-03-02       Impact factor: 4.009

5.  Performance and robustness of the Monte Carlo importance sampling algorithm using parallelized S-ADAPT for basic and complex mechanistic models.

Authors:  Jurgen B Bulitta; Cornelia B Landersdorfer
Journal:  AAPS J       Date:  2011-03-04       Impact factor: 4.009

6.  Estimation of population pharmacokinetic parameters of saquinavir in HIV patients with the MONOLIX software.

Authors:  Marc Lavielle; France Mentré
Journal:  J Pharmacokinet Pharmacodyn       Date:  2007-01-09       Impact factor: 2.745

7.  Opportunities for integration of pharmacokinetics, pharmacodynamics, and toxicokinetics in rational drug development.

Authors:  C C Peck; W H Barr; L Z Benet; J Collins; R E Desjardins; D E Furst; J G Harter; G Levy; T Ludden; J H Rodman
Journal:  J Clin Pharmacol       Date:  1994-02       Impact factor: 3.126

8.  Pharmacokinetic-pharmacodynamic-efficacy analysis of efalizumab in patients with moderate to severe psoriasis.

Authors:  Chee M Ng; Amita Joshi; Russell L Dedrick; Marvin R Garovoy; Robert J Bauer
Journal:  Pharm Res       Date:  2005-07-22       Impact factor: 4.200

9.  Evaluation of uncertainty parameters estimated by different population PK software and methods.

Authors:  Céline Dartois; Annabelle Lemenuel-Diot; Christian Laveille; Brigitte Tranchand; Michel Tod; Pascal Girard
Journal:  J Pharmacokinet Pharmacodyn       Date:  2007-01-10       Impact factor: 2.410

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.